N-(4-fluorophenyl)-4-(mesityloxy)-1,3,5-triazin-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(4-fluorophenyl)-4-(mesityloxy)-1,3,5-triazin-2-amine
• 英文别名: N-(4-fluorophenyl)-4-(2,4,6-trimethylphenoxy)-1,3,5-triazin-2-amine
• 化学式: C₁₈H₁₇FN₄O
• 分子量: 324.358
• InChiKey: CWPQKHFRGPKZCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  59.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-氟苯胺 在 四丁基硫酸氢铵 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 0.58h， 生成 N-(4-fluorophenyl)-4-(mesityloxy)-1,3,5-triazin-2-amine
  参考文献：
  名称：

  Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives

  摘要：

  Human African trypanosomiasis is causing thousands of deaths every year in the rural areas of subsaharan Africa. There is a high unmet medical need since the approved drugs are poorly efficacious, show considerable toxicity and are not easy to administer. This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds. One compound (35 (UAMC-03011)) with potent anti-trypanosomal activity and no cytotoxicity was selected for further study because of its good microsomal stability and high selectivity for Trypanosoma brucei over a panel including Trypanosoma cruzi, Leishmania infantum, and Plasmodium falciparum. In vivo pharmacokinetic parameters were determined and the compound was studied in an acute in vivo mouse disease model. One of the important leamings of this study was that the rate of trypanocidal activity is an important parameter during the lead optimization process. (C) 2018 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2018.03.048

文献信息

• Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives
  作者：Irene G. Salado、Adrienn Baán、Tomas Verdeyen、An Matheeussen、Guy Caljon、Pieter Van der Veken、Filip Kiekens、Louis Maes、Koen Augustyns

  DOI：10.1016/j.ejmech.2018.03.048

  日期：2018.5

  Human African trypanosomiasis is causing thousands of deaths every year in the rural areas of subsaharan Africa. There is a high unmet medical need since the approved drugs are poorly efficacious, show considerable toxicity and are not easy to administer. This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds. One compound (35 (UAMC-03011)) with potent anti-trypanosomal activity and no cytotoxicity was selected for further study because of its good microsomal stability and high selectivity for Trypanosoma brucei over a panel including Trypanosoma cruzi, Leishmania infantum, and Plasmodium falciparum. In vivo pharmacokinetic parameters were determined and the compound was studied in an acute in vivo mouse disease model. One of the important leamings of this study was that the rate of trypanocidal activity is an important parameter during the lead optimization process. (C) 2018 Elsevier Masson SAS. All rights reserved.